Lilly's migraine reliever Reyvow cleared for launch, beating Allergan's rival Ubrelvy to market

Lilly's migraine reliever Reyvow cleared for launch, beating Allergan's rival Ubrelvy to market

Source: 
Fierce Pharma
snippet: 

Eli Lilly won approval for its new migraine treatment Reyvow back in October, but it had to wait for Drug Enforcement Administration scheduling to launch—and now, it's ready to roll. The first-of-its-kind med for acute migraine offers relief within two hours, data show, but it'll soon face competition from the CGRP class that's now only cleared to prevent the painful episodes.